Nuclera, a UK-based biotech company, has opened a US subsidiary located in Boston, MA. This is designed to push Nuclera’s eProtein desktop bioprinter for biotherapeutics.
Dr Michael Chen, CEO and cofounder of Nuclera, said: “This site opening just outside one of the most important biotech markets is a big step towards Nuclera’s goal to make proteins accessible through desktop bioprinting. Our new facility has been specifically designed to accommodate our expanding team and will support Nuclera’s ambitious roadmap. We are proud to have operations in both the UK and the US, further strengthening our position in the global biotech space.”